In addition to aforementioned medications, ACE inhibitors, angiotensin receptor blockers (ARBs), and sodium glucose cotransporter-2 (SGLT-2) inhibitors are some of the drug classes that have been studied to be repurposed for COVID-19 treatment (128). This evidence concerns the gene SLC5A2 and COVID-19.